Key Highlights

  • EVE has signed a binding Master Compounding and Profit Share Agreement with Optimal Pharmacy Plus Stafford.
  • EVE is entitled to 75 per cent of the profit available for distribution, with Optimal receiving the remaining 25 per cent.
  • The agreement contains no upfront payments or fixed fees payable by EVE and no minimum volumes or guaranteed revenue.
  • First Supply is subject to conditions, including completion of technology transfer and validation.

EVE Health Group Limited (ASX:EVE) has entered into a binding agreement to commercialise its proprietary men's sexual health range in Australia through a pharmacy partner. The Master Compounding and Profit Share Agreement with Optimal Pharmacy Plus Stafford, announced on 10 November 2026, is the company's first formal route to supply this range to patients. The structure relies on EVE supplying its formulation technology while the pharmacy partner handles compounding, dispensing and delivery.

Commercial Structure and Profit Sharing

Under the agreement, EVE supplies its patent-pending nano-emulsion technology, technical know-how and commercial support. Optimal is responsible for sourcing ingredients, compounding, dispensing and delivering the product. Profit available for distribution is shared 75 per cent to EVE and 25 per cent to Optimal. That profit is calculated as net patient revenue, excluding GST, refunds and chargebacks, less the direct costs of compounding and delivery, including ingredients, packaging, delivery and a fixed per-unit labour rate.

The profit calculation includes no Margin or mark-up, and all rebates and savings are passed through. EVE also pays support fees to telehealth partners for their services, which are met from its 75 per cent share. The company has said it is capital-light, meaning it avoids building its own compounding operation, and it keeps ownership of its intellectual property, including improvements made under the agreement.

Market Context and Clinical Background

EVE points to telehealth as a growing channel through which patients access men's sexual health treatment. The company cites an Australian study of more than 100,000 men aged 45 and over, in which around 61 per cent reported some degree of erectile dysfunction. That study relied on self-reported questionnaire responses, so its figures reflect what men reported rather than clinically confirmed diagnoses. The company also refers to global projections and a market estimate of about US$5.7 billion for the erectile dysfunction treatment market in 2026, drawn from third-party research.

The range is based on EVE's patent-pending nano-emulsion technology and is designed to address both erectile dysfunction and premature ejaculation, two conditions that often occur together. The arrangement is separate from the company's Libbo vardenafil oral soluble film program, which continues along its planned bioequivalence and registration pathway.

Terms, Timing and Regulatory Position

The initial term runs for two years from first supply, after which the agreement renews automatically for successive 12-month periods unless either party gives 90 days' notice. Optimal is appointed as the exclusive Australian compounder for the initial products from first supply, and it must not compound or supply competing formulations. Either party can terminate for an unremedied material breach, and EVE can end the agreement if first supply has not occurred within three months of signing, other than because of its own default.

The company has been clear that the agreement does not include minimum volumes or guaranteed revenue. EVE says it cannot yet estimate the Revenue the agreement may generate, as this depends on the timing of first supply, prescribing decisions by independent clinicians, patient demand, pricing and costs. Compounded medicines are prepared for individual patients against a valid prescription, are not entered on the Australian Register of Therapeutic Goods, and have not been assessed by the Therapeutic Goods Administration for safety, quality or efficacy.

Risks and Next Steps

EVE and Optimal must now complete readiness steps for first supply and engage telehealth partners to reach patients. Prescribing decisions will remain with independent clinicians, and each product will be compounded individually. Revenue will depend on how prescribing volumes develop, and the lack of TGA assessment for compounded medicines means the regulatory framework around the product will remain a central consideration for shareholders.

Final Word

The agreement gives EVE a defined pathway to market for its men's health range without the cost of building a compounding facility, while preserving its intellectual property and the option of pursuing a registered product later. The absence of guaranteed volumes, the conditions attached to first supply and the non-registered status of compounded medicines mean the financial outcome of the arrangement remains uncertain. Progress on technology transfer and the first supply date will be the clearest early indicators of how the model performs.